Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6299MR)

This product GTTS-WQ6299MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors, research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6299MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14537MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ10770MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ9670MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ12895MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ1488MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ6017MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ7063MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ11288MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW